HIGH GRADE GLIOMA (III OR IV)
Clinical trials for HIGH GRADE GLIOMA (III OR IV) explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE GLIOMA (III OR IV) trials appear
Sign up with your email to follow new studies for HIGH GRADE GLIOMA (III OR IV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New weapon tested against deadly brain cancers that Won't quit
Disease control Not yet recruitingThis is an early-stage study to test the safety and find the right dose of a new drug called FZ-AD005 for adults with aggressive brain tumors that have come back or stopped responding to standard treatments. The study will enroll about 40 people with high-grade gliomas, including…
Matched conditions: HIGH GRADE GLIOMA (III OR IV)
Phase: PHASE1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for kids with devastating brain cancers: targeted drug trial launches
Disease control Not yet recruitingThis study is testing whether a drug called tovorafenib can help children and young adults live longer after being diagnosed with aggressive brain tumors, including a type called DIPG. The drug is given after standard radiation treatment and targets tumors with specific genetic c…
Matched conditions: HIGH GRADE GLIOMA (III OR IV)
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Glowing drug lights up brain tumors for surgeons
Knowledge-focused Not yet recruitingThis early study aims to see if a cancer drug (nivolumab) can be made to glow with a special dye, allowing doctors to see exactly where it goes in the brain during surgery for aggressive tumors called high-grade gliomas. The main goals are to check if this glowing version of the …
Matched conditions: HIGH GRADE GLIOMA (III OR IV)
Phase: EARLY_PHASE1 • Sponsor: Eben Rosenthal • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC